Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients... PharmacoEconomics Open (2017) 1:279–290 https://doi.org/10.1007/s41669-017-0031-6 ORIGINAL RESEARCH ARTICLE Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden 1 1 1 2 • • • • Ugne Sabale Mattias Ekman Daniel Thunstro¨m Claire Telford Christopher Livings Published online: 1 June 2017 The Author(s) 2017. This article is an open access publication Abstract €33,808, €33,883, and €49,225 per QALY with incre- Objectives In Sweden, breast cancer (BC) represents 30% mental costs of €13,283, €14,986, and €13,862, and of newly diagnosed cancers and is the most common incremental QALYs of 0.393, 0.442, and 0.282, respec- cancer in women. For hormone-dependent BC, endocrine tively. Incremental cost per life-year (LY) gained €21,312 therapies varying in efficacy and price are available. The (incremental LY of 0.623), €20,338 (incremental LY of aim of this study is to assess the cost effectiveness of 0.737), and €27,854 (incremental LY of 0.498) for fulvestrant 500 mg as a second-line hormonal therapy for respective comparators. Applying the upper and lower postmenopausal women with estrogen receptor-positive credible intervals for PFS/OS from the meta-analysis had metastatic or locally advanced BC versus letrozole, anas- the greatest effect on the ICER in the sensitivity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics - Open Springer Journals

Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

Loading next page...
 
/lp/springer_journal/economic-evaluation-of-fulvestrant-500mg-compared-to-generic-aromatase-igkRarviZU
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes
ISSN
2509-4262
eISSN
2509-4254
D.O.I.
10.1007/s41669-017-0031-6
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics Open (2017) 1:279–290 https://doi.org/10.1007/s41669-017-0031-6 ORIGINAL RESEARCH ARTICLE Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden 1 1 1 2 • • • • Ugne Sabale Mattias Ekman Daniel Thunstro¨m Claire Telford Christopher Livings Published online: 1 June 2017 The Author(s) 2017. This article is an open access publication Abstract €33,808, €33,883, and €49,225 per QALY with incre- Objectives In Sweden, breast cancer (BC) represents 30% mental costs of €13,283, €14,986, and €13,862, and of newly diagnosed cancers and is the most common incremental QALYs of 0.393, 0.442, and 0.282, respec- cancer in women. For hormone-dependent BC, endocrine tively. Incremental cost per life-year (LY) gained €21,312 therapies varying in efficacy and price are available. The (incremental LY of 0.623), €20,338 (incremental LY of aim of this study is to assess the cost effectiveness of 0.737), and €27,854 (incremental LY of 0.498) for fulvestrant 500 mg as a second-line hormonal therapy for respective comparators. Applying the upper and lower postmenopausal women with estrogen receptor-positive credible intervals for PFS/OS from the meta-analysis had metastatic or locally advanced BC versus letrozole, anas- the greatest effect on the ICER in the sensitivity

Journal

PharmacoEconomics - OpenSpringer Journals

Published: Jun 1, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off